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Abstract
Background: Chinese herbal medicine formula Yu ping feng san (YPFS) is commonly used for allergic rhinitis (AR).
Previous review had summarized the effectiveness and safety of YPFS, however without any subgroup analysis
performed to provide detailed evidence for guiding clinical practice. YPFS was recommended for the management
of AR by Chinese medicine clinical practice guideline, but the treatment duration of YPFS was also not specified.
The aim of this study is to evaluate the effectiveness and safety of YPFS in treating adult AR with the most recent
evidence, and attempt to specify the duration of utilisation through subgroup meta-analyses.
Methods: Seven databases were searched from their inceptions to September 2017. Randomized controlled trials
(RCTs) evaluating YPFS for adult AR were included. Methodological quality of studies was assessed using the
Cochrane risk of bias tool. Meta-analysis and subgroup meta-analyses were conducted for evaluating the
effectiveness of YPFS. The Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach was used for rating the quality of evidence.
Results: Twenty-two RCTs involving 23 comparisons were included in this review. YPFS was compared to placebo,
pharmacotherapy, and used as an add-on treatment compared to pharmacotherapy. Meta-analyses were feasible
for the outcomes of four individual nasal symptom scores and “effective rate”. Four individual nasal symptom scores
decreased after YPFS’ combination treatment: itchy nose (MD-0.46, 95% CI[−0.50, −0.42]), sneezing (MD-0.41, 95%
CI[−0.47, −0.35]), blocked nose (MD-0.46, 95% CI[−0.54, −0.39]) and runny nose (MD-0.42, 95% CI[−0.58, −0.26]).
Based on “effective rate”, meta-analysis showed that YPFS did not achieve better effect than pharmacotherapy
(RR1.07, 95%CI [0.94, 1.22), but its combination with pharmacotherapy seemed more effective than
pharmacotherapy alone (RR1.27, 95%CI [1.19, 1.34]) (low quality). Subgroup analysis suggested that YPFS was
not superior to the second-generation antihistamine (RR1.04, 95%CI [0.90, 1.19]) (low quality). Further, YPFS’
combination treatment seemed more beneficial when it was used for more than three weeks (RR1.15, 95%CI
[1.01, 1.32]). In addition, YPFS was well-tolerated for treating adult AR.
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Conclusion: Chinese herbal medicine formula YPFS seems beneficial for adult AR. This potential benefit need
to be further evaluated by more rigorous RCTs.
Keywords: Yu ping feng san, Chinese herbal medicine, Allergic rhinitis, Treatment duration, Systematic review,
Meta-analysis
Background
Allergic rhinitis (AR) is the most common type of non-
infectious rhinitis; it is defined as a “symptomatic
disorder of the nose induced by the IgE-mediated in-
flammation after allergen exposure” [1]. AR is character-
ized mainly by nasal symptoms including sneezing,
itching, rhinorrhoea and nasal congestion, as well as a
group of non-nasal symptoms involving eyes, ears,
throat or chest. AR patients may also develop sinusitis
and asthma, or be accompanied by malaise, weakness,
and fatigue [2, 3]. Globally, AR affects 10% to 20% of the
population, and an increase of the prevalence has been
observed in the past 40 years [1, 4]. Clinically, AR is one
of the most common diseases affecting adults [5], and it
is considered a major chronic respiratory disease due to
its high prevalence, impairments on patients’ quality of
life (QoL) and work/school performance, substantial
economic impact and its co-morbidities [1, 6].
Allergic rhinitis has traditionally been categorized as
seasonal or perennial types according to the predilection
time and triggering allergens, or may be classified as
intermittent or persistent types based on its frequency
and severity. However, both of these classifications have
certain limitations [1, 5–7]. Regardless of the classifica-
tion types, their clinical management are all same. Rec-
ommended by the most recent clinical guideline,
effective treatments of AR are topical steroids, oral anti-
histamines, and immunotherapy [5]. This guideline also
pointed out that Chinese herbal medicine (CHM) has
often been utilized for managing AR in clinical practice,
although the evidence supporting its efficacy and mech-
anism of action is uncertain [5]. As suggested by a sys-
tematic review published in 2012, CHM might be more
effective than placebo for persistent allergic rhinitis, but
a confirmed conclusion could not be drawn since all in-
cluded studies suffered certain methodological limita-
tions [8].One CHM formula, Yu ping feng san (YPFS),
was recommended by Chinese medicine clinical practice
guideline to manage AR despite its classification and se-
verity, but the effective treatment duration is not clear
[9]. YPFS formula contains three key herbs: Astragalus
membranaceus (huang qi), Rhizoma Atractylodis Macro-
cephalae (bai zhu) and Radix Ledebouriellae Divaricatae
(fang feng) [10]. In clinical practice, YPFS usually is used
together with other herbs, e.g., Lilymagnolia (xin yi),
Fructus xanthii (cang er zi) and Radix Angelicae
Dahuricae (bai zhi) etc. The effectiveness and safety of
YPFS for AR treatment has been investigated by a num-
ber of clinical studies, and been summarized by a review
article published in Chinese [11]. Although the overall
effectiveness of YPFS seems promising, the treatment
details were not suggested due to the lack of subgroup
analyses. Therefore, in depth meta-analyses of current
evidence are needed for guiding the use of YPFS for
adult AR treatment in clinical practice.
Methods
The review protocol was registered on PROSPERO
(CRD42015024821), and the review was constructed fol-
lowing the PRISMA guidelines (Additional file 1).
Study selection criteria
This systematic review was designed to evaluate the ef-
fectiveness and safety of CHM formula YPFS for AR. No
limits on language and publication type were placed on
study selection. Studies were considered if they recruited
adult AR participants (aged 18 years and above) without
classification limited. Included studies were RCTs com-
paring oral YPFS in any preparation forms to placebo
CHM or pharmacotherapy being recommended by clin-
ical practice guidelines [1, 7], or comparing the combin-
ation of YPFS and pharmacotherapy to the same
pharmacotherapy. If YPFS was used together with other
CHM herbs, only the studies using YPFS as the chief
formula with other herbs as additional modification were
included.
Studies were included if they reported one of the pre-
defined outcomes, these are: the primary outcome mea-
sures being total nasal symptom score (TNSS) or indi-
vidual nasal symptom scores; the secondary outcomes
are effective rate (a composite outcome measure which
calculates the change of nasal symptoms scores and
nasal signs), QoL, recurrence rate in follow-up phase,
serum specific immunoglobulin E (sIgE) level, serum
interleukin 4 (IL-4), and adverse events (AEs).
Search strategy
A comprehensive search was conducted in seven major
English and Chinese databases from their inceptions to
September 2017. Searched databases are: PubMed,
Cochrane Central Register of Controlled Trials (CEN-
TRAL), EMBASE, Chinese Biomedicine (CBM), China
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Network Knowledge Infrastructure (CNKI), Wanfang
Database and Chinese Scientific Journals Database
(VIP). Reference lists of all full text articles were hand-
searched for additional studies. The ongoing trials were
searched from clinical trial registries. The search strat-
egies for PubMed and Chinese Databases are provided
as examples (see Additional file 2). Abstracts and full
texts were screened for eligibility by two authors (QL
and CSZ) independently according to the selection cri-
teria. Disagreement was solved through discussion with
the third author (LY).
Data extraction
Data were extracted and entered into a pre-defined Excel
spread sheet, including study design, participants’ demo-
graphic data, details of CHM and control treatments,
outcome data and AEs.
Methodological assessment
Two authors (QL and LY) assessed the methodological
quality of the included studies independently using the
risk of bias tools according to the Cochrane Handbook
version 5.1.0 [12]. Disagreements were resolved through
discussion with another author (XG). Each item was
assessed as low, high or unclear risk, with reasons re-
corded to support the judgments.
Statistical analysis
The RevMan 5.3 software was used for performing
meta-analyses. Studies were grouped for analyses ac-
cording to their comparisons and outcome measures.
Dichotomous data were expressed as risk ratio (RR) and
continuous data were presented as mean difference
(MD), both with 95% confidence intervals (CI). A fixed-
effect model was used when heterogeneity (I2) was less
than 50%; otherwise a random effects model was ap-
plied. Subgroup analysis was performed based on the
type of pharmacotherapy medicine used in the control
groups (e.g., second-generation antihistamine, intranasal
glucocorticosteroids) and treatment duration (two weeks
or more than three weeks). Publication bias was assessed
using a funnel plot and Egger’s test where more than ten
trials in a meta-analysis.
GRADE
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach [13] was
used to summarize and rate the quality of evidence.
Summary of Findings (SOF) tables were prepared using
the online software program “GRADE pro GDT”
(https://gradepro.org/). The main comparisons being
assessed using GRADE methods were identified through
discussion.
Results
In total, 1244 records were obtained through database
searches, and 334 potentially relevant articles were
identified after screening titles and abstracts. Accord-
ing to the selection criteria, 312 articles were further
excluded. Twenty-two RCTs were included in the re-
view [14–35], twenty of them were included meta-
analyses [16–35]. Twenty-one included trials were
conducted in the mainland China and published in
Chinese [15–35], and one was conducted in China
Hong Kong and published in English [14]. The search
and study selection process is shown in Fig. 1, and
the characteristics of included RCTs are presented in
Table 1.
Participants
In total, 2309 participants with AR were involved in the
22 RCTs, 309 participants were diagnosed with perennial
allergic rhinitis, and 2000 participants were AR without
specified subtype. All participants aged between 18 to
70 years. Of the reported gender information, there were
a total of 1153 males and 1098 females. Participants
were allocated to the YPFS group (n = 552), placebo
group (n = 126), pharmacotherapy group (n = 1044) and
the combination of CHM and pharmacotherapy group
(n = 587). Five studies did not provide information on
participants’ duration of disease [17, 21, 26, 29, 31], the
remaining 17 RCTs reported the duration of disease with
a median of 4.5 years.
Interventions
Nine studies employed the original YPFS formula of only
three herbs as treatment [16, 21, 24–26, 31, 33–35], the
remaining 13 studies used modified YPFS formulas.
The dosage and composition of YPFS formulas used in
different studies are presented in Table 2. The prepar-
ation forms of the CHM were decoctions (10 studies)
[17, 18, 20, 22, 23, 27–30, 32], granule (eight studies)
[19, 21, 25, 26, 31, 33–35], capsule (one study) [16],
pill (one study) [24], and liquid extract (two studies)
[14, 15]. In regards to the comparator, two studies
compared YPFS to placebo [14, 15], seven studies com-
pared YPFS to pharmacotherapy [16–22], 12 studies
compared the combination of YPFS and pharmacother-
apy to pharmacotherapy alone [24–35], and one three-
arm study [23] contained both pharmacotherapy and
YPFS plus pharmacotherapy as controls. In addition,
two studies had an arm of a different CHM formula
which are not included in our review [14, 15].
Pharmacotherapy being used as comparators were: 1)
oral [17–22, 24, 28–30, 34, 35] or intranasal [23, 32, 33]
second generation H1-antihistamines, 2) intranasal glu-
cocorticosteroids [26, 31], and 3) the combination of
Luo et al. BMC Complementary and Alternative Medicine  (2017) 17:485 Page 3 of 20
second generation H1-antihistamines and intranasal glu-
cocorticosteroids [16, 25, 27].
Outcomes
The primary outcome measures of individual nasal
symptom scores were reported in four studies [29, 32,
34, 35]. In terms of the secondary outcome measures, ef-
fective rate was reported in 20 studies [15–32, 34, 35],
with two methods of calculating the effective rate being
used as stated in Chinese clinical guidelines [36–39]. Pa-
tients’ QoL using Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ) score was assessed by one study
[14]. Reported laboratory tests results were serum sIgE
[15] and IL-4 [15, 16, 30, 33, 34]. In addition, the recur-
rence rate in follow-up phase was reported in two
studies [18, 20].
Treatment duration and follow-up
All included studies provided treatment of equal dur-
ation to the intervention and control groups. The treat-
ment duration was two weeks or fifteen days in eight
studies [17, 19–21, 23, 25, 31, 34], four weeks or one
month in 12 studies [14, 16, 18, 22, 24, 26–30, 33, 35],
three weeks [32] and eight weeks [15] each in one study.
Six studies [14, 18, 20, 25, 27, 29] reported a post treat-
ment follow-up phase, being one month [20], eight
weeks [25], three month [14, 27], six months [29] and
one year [18].
Dropouts
Three studies reported dropouts during treatment phase
with reasons provided [14, 28, 30]. None of the dropouts
was due to serious AE. The other 19 studies were con-
sidered to have no dropouts since they reported equal
numbers of participants at randomization and study
completion.
Risk of bias assessment
Eight studies were assessed as “low” risk for “se-
quence generation” since they used random number
“tables” [14, 16, 20, 22, 23, 29, 33, 35], others were
“unclear”. For “allocation concealment”, one study
was “low” risk because it used a sealed envelope
method [14], others were “unclear” due to lack of in-
formation. One study employed placebo control and
made effort to blind participants, personnel and outcome
assessors, thus this study was assessed as “low” risk for
these items [14]; the other 21 studies were “high” risk
for “blinding of participants and personnel” and “un-
clear” risk for “blinding of outcome assessors”. All
studies were “low” risk for the “incomplete outcome
data”, since they were considered having no dropouts
Fig. 1 Flow chart of study selection process
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[15–27, 29–35], or reported similar number of dropouts
from both groups which was unlikely to cause bias
[14, 28, 30]. One study reported all outcomes pre-
defined in its registered protocol therefore it received a
“low” risk for the “selective outcome reporting” [14],
others were “unclear”. Due to lacking of information, all
studies were “unclear” for “other bias” focusing on the
funding resources.
Effectiveness
The effectiveness of YPFS were firstly analysed according
to the comparators as follow. All meta-analyses results
are summarised in Table 3.
YPFS versus placebo
Two studies compared YPFS with oral placebo [14, 15].
Meta-analysis was not possible because they reported
data on different outcomes.
One study reported data on RQLQ, it was found that
the post-treatment total RQLQ score of the YPFS group
was lower than that of the placebo group (n = 159, MD-
8.57, 95%CI [−16.37, −0.77]) [14]. Another study re-
ported post-treatment data on effective rate, serum sIgE
and IL-4. Significant difference between the YPFS group
and the placebo group was found for all these outcomes
(n = 86, effective rate: RR13.33, 95%CI [4.46, 39.83];
sIgE: MD-16.18, 95%CI [−22.50, −9.86]; IL-4: MD-19.65,
95%CI [−25.32,-13.98]) [15]. However, these results are
only from single study, the small sample size and wide
confidence interval makes the results unconvinced.
YPFS versus pharmacotherapy
Seven studies compared YPFS to pharmacotherapy
[16–22], and one three-arm study also contained this
comparison [23]. None of these studies reported nasal
symptom scores.
All these studies reported post-treatment data on ef-
fective rate, the overall meta-analysis showed that YPFS
did not achieve superior effect than overall pharmaco-
therapy (n = 833, RR1.07, 95%CI [0.94, 1.22], I2 = 70%)
[16–23]. Subgroup analyses were conducted to further
explore the effectiveness of YPFS comparing to different
types of pharmacotherapy. It was found that, when com-
paring YPFS to the second-generation antihistamines,
there was no significant difference between two groups
for the outcome of effective rate (n = 613, RR1.04,
95%CI [0.90, 1.19], I2 = 64%) [17–23]. On the other
hand, one study showed that YPFS was more effective
than the combination of the second-generation antihis-
tamine and intranasal glucocorticosteroids (n = 220,
RR1.27, 95%CI [1.10, 1.48]) [16] (Fig. 2).
Subgroup analysis based on treatment duration was
also conducted. Results showed that, in terms of the ef-
fective rate, there was no significant difference between
the YPFS and pharmacotherapy when it was tested for
two weeks (n = 410, RR1.04, 95%CI [0.92, 1.18], I2 = 6%)
[17, 19–21, 23]; or being tested for more than three
weeks (n = 423, RR1.08, 95%CI [0.82, 1.42], I2 = 90%)
[16, 18, 22] (Fig. 3).
In addition, one study found that YPFS achieved better
effect than intranasal glucocorticosteroids for IL-4
(n = 220, MD-37.94, 95%CI [−49.47, −26.41]) [16]. An-
other study reported the recurrence rate at the end of
follow-up phase, it was found that the number of recur-
rence of the YPFS group was less than that of pharmaco-
therapy (Cetirizine) (n = 103, RR0.37, 95%CI [0.18,
0.78]) [18].
YPFS plus pharmacotherapy versus pharmacotherapy
Twelve studies compared the combination of YPFS and
pharmacotherapy to pharmacotherapy alone [24–35], and
one three-arm study also contained this comparison [23].
For the primary outcome measure, four studies using
second-generation antihistamines as control reported
data on individual symptoms scores [29, 32, 34, 35]. It
was found that the combined intervention was more ef-
fective than second-generation antihistamines alone for
four nasal symptoms: itchy nose (n = 418, MD-0.46,
95%CI [−0.50, −0.42], I2 = 0%), sneezing (n = 418, MD-
0.41, 95%CI [−0.47, −0.35], I2 = 54%), blocked nose
(n = 418, MD-0.46, 95%CI [−0.54, −0.39], I2 = 60%) [29,
32, 34, 35] and runny nose (n = 318, MD-0.42, 95%CI
[−0.58, −0.26], I2 = 70%) [29, 32, 35].
Meta-analysis was also feasible for the outcome of ef-
fective rate. Of these 1 comparisons, meta-analysis
showed that the combination was more effective than
pharmacotherapy alone (n = 1077, RR1.27, 95%CI [1.19,
1.34], I2 = 22%) [23–32, 34, 35]. Subgroup analysis on ef-
fective rate was conducted according to the pharmaco-
therapy used in the control groups. The results showed
that the combination was more effective than different
types pharmacotherapy as follow: the combination ver-
sus second-generation antihistamines (n = 727, RR1.28,
95%CI [1.19, 1.37], I2 = 43%) [23, 24, 28–30, 32, 34, 35]
and the combination versus the second-generation anti-
histamine plus intranasal glucocorticosteroids (n = 225,
RR1.29, 95%CI [1.14,1.46], I2 = 0%) [25, 27]. However,
the combined intervention was not superior to intrana-
sal glucocorticosteroids alone (n = 125, RR1.15, 95%CI
[0.97, 1.36], I2 = 0%) [26, 31]. (Fig. 4).
Subgroup analysis for effective rate was performed
based on the treatment duration [23–31, 34, 35]. Super-
ior effects towards the combination therapy was found
when it was tested for more than three weeks, (n = 725,
RR1.15, 95%CI [1.01, 1.32], I2 = 74%) [24, 26–30, 32,
35], but it was not found in the subgroup of two weeks
treatment (n = 353, RR1.13, 95%CI [0.84, 1.54],
I2 = 88%) [23, 25, 31, 34] (Fig. 5).
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Fig. 3 Forest plot: YPFS versus pharmacotherapy (effective rate based on treatment duration). Legends: 2w: two weeks; ≥3w: three weeks or
more than three weeks
Fig. 2 Forest plot: YPFS versus pharmacotherapy (effective rate based on pharmacotherapy). Abbreviation: IGCS: intranasal glucocorticosteroids
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Fig. 5 Forest plot: YPFS plus pharmacotherapy versus pharmacotherapy (effective rate based on treatment duration). Legends: 2w: two weeks;
≥3w: three weeks or more than three weeks
Fig. 4 Forest plot: YPFS plus pharmacotherapy versus pharmacotherapy (effective rate based on pharmacotherapy). Abbreviation: IGCS:
intranasal glucocorticosteroids.
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In addition, biomarker IL-4 was reported by three
studies and it showed that the YPFS and second-
generation antihistamines combination treatment were
superior to second-generation antihistamines alone
(n = 231, MD-14.43, 95%CI [−28.58, −0.29]) [30, 33, 34].
Safety
Ten studies did not report information on AEs [15,
17–21, 27, 32–34]. Eight studies reported there was
no AE occurred in both groups [16, 22, 24–26, 28,
30, 35]. The remaining four studies reported AEs in
treatment group [14, 23, 29, 31], and control groups
[23, 29, 31] during the treatment phase. According
to these studies, the AEs possibly associated with the
use of YPFS were acne and abdominal distension
[14]; while the AEs possibly caused by pharmaco-
therapy included dryness in the nasal cavity [23],
local mucosa irritation [31], sedation [31], skin rash
[29, 31], vomit and nausea [29]. All above AEs were
transient and no medical intervention was required.
Serious AE was not reported by any study. It was worth
noting that the number of AEs occurred in the combin-
ation group was less than that of the pharmacotherapy
group. For example, one study reported five cases of
AEs in the combination group and 12 cases in the
pharmacotherapy group [29], and another study re-
ported three cases of AEs in the combination group
and four cases in the pharmacotherapy group [31].
These studies concluded that adding YPFS to pharma-
cotherapy is safe and it may be beneficial for reducing
the AEs caused by pharmacotherapy. All detailed infor-
mation of AEs is provided in Table 1.
Publication bias
The publication bias could not be assessed for the
comparison of YPFS versus pharmacotherapy since
there were not enough studies included in one meta-
analysis. For the comparison of YPFS plus pharmaco-
therapy vs. pharmacotherapy alone, there were 12 tri-
als in the meta-analysis of effective rate. No
publication bias was detected based on the funnel
plot (Fig. 6) and the Egger’s test (t = 1.30, 95% CI
[−1.26, 4.79], p = 0.223).
GRADE for the main comparisons of YPFS
GRADE assessment was conducted for two main com-
parisons. The quality of evidence was low. Table 4 sum-
marises the results.
Discussion
This systematic review evaluated RCTs of CHM YPFS
including the most recently published articles. Studies
compared CHM YPFS to placebo or pharmacotherapy,
and those used YPFS as add-on therapy were all in-
cluded in our evaluation. The evidence of YPFS effect-
iveness has been revealed through meta-analyses.
Effectiveness and safety of YPFS
In this review, meta-analyses were feasible for the out-
comes of four individual nasal symptom scores and “ef-
fective rate”. Based on these outcomes, it was found
that: 1) in terms of the nasal symptoms, adding YPFS to
the second-generation antihistamines achieved better
treatment effects (low quality evidence); 2) for “effective
rate”, although YPFS was not superior to
Fig. 6 Funnel plot: YPFS plus pharmacotherapy versus pharmacotherapy (effective rate)Funnel plot: YPFS plus pharmacotherapy versus
pharmacotherapy (effective rate). Abbreviation: IGCS: intranasal glucocorticosteroids
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pharmacotherapy, adding YPFS to common pharmaco-
therapy was also more effective than using pharmaco-
therapy alone. Further, subgroup analysis showed that
there was no significant difference between YPFS and
the second-generation antihistamine in terms of “effect-
ive rate” (low quality evidence).
In order to provide evidence for the duration of clin-
ical administration, subgroup analysis regarding the
treatment duration was conducted. Our results showed
that adding YPFS to pharmacotherapy was beneficial
when it was administered for more than three weeks,
but this was not seen in the studies of only two weeks
treatment. It is worth noting that, there has been experi-
mental research evidence showing that six days’ high
and middle dosages of YPFS powder significantly in-
creased the IFN-γ, the antibody of infectious laryngotra-
cheitis and the immune organ indexes, and also reduced
IL-4 in chickens [40]. One study reported that 14 days
of oral YPFS could stimulate immune responses in aller-
gic rhinitis mice [41]. Another study reported that after
five to seven days intervention, different concentration
of the glucosidic which extracted from YPFS produced
anti-inflammatory and immune-regulatory effects [42].
These experimental studies indicated that YPFS alone
may show immune-modulatory and anti-inflammatory
effects after one to two weeks. In clinical management
of AR, pharmacotherapies usually are fast-acting for
symptom control but leaving 10% to 20% AR patients to
endure bothersome symptoms [43, 44]. Our results
suggest that, although YPFS is not superior to pharma-
cotherapy, adding CHM YPFS to common pharmaco-
therapy for at least three weeks is helpful to improve the
overall symptoms. Since YPFS has been recommended
as AR management by current Chinese Medicine clin-
ical practice guideline [9], but without recommendation
on the treatment duration, our results may potentially
have filled this gap and provide indication for further
clinical practice. Nevertheless, these finding was only
based on the outcome of “effective rate” since there
were not enough data on nasal symptoms scores sup-
porting these analyses. Further studies using globally
well-accepted outcome measures to assess the treat-
ment effects at different time points are needed to con-
firm such findings.
Reported AEs caused by YPFS were mild and transi-
ent. It was also reported that adding YPFS could reduce
the number of AEs caused by cetirizine [29] or budeso-
nide aerosol [31], though detailed explanation was not
provided by these studies. Similar findings were reported
by other clinical trials of YPFS for AR management
[45, 46] but without further exploration of the mech-
anisms. It is worth noting that some toxicity tests of
YPFS also suggested that its toxicity is either minor
or without any adverse effects [47, 48].
Potential mechanisms of YPFS
Results from experimental studies showed that YPFS re-
duced the eosinophilic cells’ infiltration and degranula-
tion reaction, decreased the tissue edema [49, 50], and
reduced the immune factors including histamine, IgE,
IL-4 and tumor necrosis factor- α (TNF-α) in serum
[50]. Other researches indicated that YPFS was effective
for AR through down-regulating the activity of IL-6 and
TNF-α [51], activating interleukin 3 (IL-3), growth factor
of mast cells, and inhibiting granulocyte colony stimulat-
ing factor (GM-SCF) and an inhibitory factor of mast
cells proliferation [52]. IL-4 is one of the important Th2
cytokines related to AR, it can accelerate the synthesis of
B cell and secrete a large number of IgE [7]. The result
from five included studies in this review illustrated that
the IL-4 level decreased after YPFS or its combination
treatments [15, 16, 30, 33, 34], and one of these studies
also reported the sIgE level declined after YPFS treat-
ment [15]. Furthermore, a review article [53] suggested
that YPFS may lead to immunoregulatory effects
through the following pathways: 1), to promote the gen-
eration of IgA and IgG, the peripheral blood levels of
CD3+, CD4+ and CD4+/CD8+; 2), to increase the amount
of C3, C4 and the receptor of C3b, and activate the com-
plement system involved in immune response; 3), to
protect the phagocytosis of macrophage; and 4) to regu-
late the cyclic adenosine monophosphate (cAMP) in the
cells of mice spleen bi-directionally.
There has been evidence showing that glucosides were
the principal active ingredients of YPFS which are re-
lated to the anti-inflammatory and immunoregulatory
effects [42], and claycosin and formononetin may be the
effective compounds which could produce the anti-
inflammatory function by reducing thymic stromal lym-
phopoietin production via regulating Nuclear factor
(NF)-κB activation [54].
Furthermore, the three chief herbs of YPFS (huang qi,
fang feng, bai zhu) have also been researched previously.
Studies found that these herbs may have certain anti-
allergy and anti-inflammatory effects [55–58]. For in-
stance, in mice with allergen-induced airway hypersensi-
tivity, huang qi injection suppressed the allergic reaction,
enhanced interferon-gamma levels (important immune
responsive cytokine) and decreased allergen-induced ele-
vations of important allergy related interleukins IL-5 and
IL-13 [53]. Aqueous extracts of huang qi inhibited nitric
oxide production in lipopolysaccharide -stimulated mur-
ine macrophage RAW 264.7 cells in a dose-dependent
manner and this may be associated with the inhibition
of inducible nitric oxide synthase mRNA expression
[56]. In RAW 264.7 cells, fang feng compound anomalin
reduced several pro-inflammatory cytokines, including
tumor necrosis factor-α and IL-6, by inhibiting NF-κB
DNA binding [57]. Five bai zhu compounds
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(atractylenolide III 1, atractylenolide I 2, 14-acetoxy-
12-senecioyloxytetradeca-2E,8E,10E–trien-4,6-diyn-1-ol 3,
14-acetoxy-12-alpha-methylbutyl-2E,8E,10E–trien-4,6-
diyn-1-ol 4 and 14-acetoxy-12-beta-methylbutyl-
2E,8E,10E–trien-4,6-diyn-1-ol 5) significantly inhibited
mice ear edema induced by xylene, showing anti-
inflammatory activities [58].
In brief, there has been certain pre-clinical evidence
supporting the use of YPFS for AR management due to
its anti-inflammatory and immunoregulatory function.
More details about its mechanism and the active com-
pounds of YPFS are yet to be explored.
Limitations of the included studies
Proper randomization and allocation is essential to reduce
selection bias for randomized controlled trials. However,
in our systematic reviews, only 36.4% of the included stud-
ies (eight trials) applied appropriate methods for sequence
generation, and only 4.5% (one trial) for allocation con-
cealment. Blinding of participants, personnel and outcome
measures was only achieved by one study, while other
studies did not utilize proper placebo control to unsure
blinding, and therefore they were not free of performance
bias or detection bias.
In regards to the outcome measures, it was found the
individual nasal symptom scores was reported by four
studies but without TNSS being reported, and QoL was
only reported by one study, while the “effective rate” was
reported by the majority of the included studies. The “ef-
fective rate” assesses the proportion of participants who
had achieved certain improvement of the nasal symp-
toms and signs. Considering that this outcome measure
only reflects the overall improvement, it makes it indir-
ect to compare the effectiveness results of these studies
to other RCTs which reported data on nasal symptom
scores and QoL, even though this outcome measure was
recommended by several previous clinical guidelines
[36–39, 59] and had been widely used in China.
Considering AR is a chronic and recurrent condition, the
long-term effects or the recurrence rate after treatment is
of clinicians’ interests. Two included studies reported data
on the recurrence rate in follow-up phase [18, 20]. How-
ever, there is no clear definition of “recurrence” stated by
these studies. Further studies should consider using the
internationally well-accepted outcome measures to evaluate
the long-term treatment effects of YPFS, for example, the
nasal symptom scores and QoL.
In terms of clinical trial reporting, none of the in-
cluded study reported all items recommended by CON-
SORT 2010 and its Extension for Herbal Intervention
[60, 61]. Also, in the absent of trial registration informa-
tion or published protocol of the included studies, evalu-
ation of selective reporting bias was not applicable in all
of the included studies.
All these limitations reduced the certainty of our re-
sults. Future research should take all these aspects into
consideration and improve the methodological quality of
clinical trials’ design and conduct.
Strengths and limitations of this review
The review synthesised the most recent clinical research
following rigorous methodology recommended by the
Cochrane Handbook, with GRADE approach being used
to assess the quality of evidence. This review focused on
YPFS treating adult AR, it not only included studies com-
paring YPFS to placebo or pharmacotherapy, but also
evaluated the add-on effects of YPFS to pharmacotherapy.
Outcome measures included symptoms scores, QoL, ef-
fective rate, recurrence rate, as well as objective outcomes
such as serum sIgE and IL-4.
However, a few limitations downgraded the certainty
of our results, they are: 1). The majority of included
studies (21 out of 22) were all conducted in China and
published in Chinese. 2).outcome measures in most in-
cluded studies were not consistent with international
guidelines. This leads to indirectness when interpreting
the findings; 3). the overall methodological quality of in-
cluded studies was low; 4). the long-term effects of YPFS
were uncertain due to the lack of follow-up phase of
most studies.
Implication for clinical practice and further research
The results of this review suggest that YPFS is effective for
the management of adult AR as on add-on therapy. Clin-
ical practice could consider adding oral YPFS to routine
pharmacotherapy management and it may improve the ef-
fectiveness and safety of routine pharmacotherapy. A cor-
relation of treatment duration and effects of YPFS was
observed in this review, however, it requires further ex-
ploration. The mechanism of YPFS herbs and their active
compounds are also worth more investigation.
Nevertheless, although YPFS in general is effective re-
garding individual nasal symptoms and the overall “effect-
ive rate”, but there is insufficient data supporting the
effectiveness towards TNSS and QoL. Further research
should consider employing outcome measures recom-
mended by international guidelines (nasal symptom scores
and QoL) to evaluate the effectiveness of YPFS. A follow-
up phase with well-accepted outcome measures is also im-
portant to confirm the long-term effects of YPFS. Lack of
blinding is the major methodological flaw of most in-
cluded studies in this review, further research should con-
sider adapting placebo control and making efforts to the
blinding of participants and outcome assessors.
In addition, although it was seen that adding YPFS to
pharmacotherapy may reduce the common AEs caused
by pharmacotherapy, the mechanism of such herb-drug
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interaction is unknown. This may be worth exploring for
future research to provide evidence of the safety aspect.
Conclusion
Oral CHM YPFS seems to have add-on effects to
pharmacotherapy for the treatment of adult AR, when
it was administered for at least three weeks. Further,
the use of YPFS in clinical practice is safe. Also, there
has been available pre-clinical evidence supporting the
use of YPFS and the three chief herbs for AR. How-
ever, the overall methodological quality of included
studies was low. More RCTs following rigorous meth-
odology and using internationally well-accepted out-
come measures are needed to further define the
effectiveness of YPFS.
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